Chinese venture firm Legend Capital leads $100m round for Innovent Biologics

Beijing-headquartered Legend Capital has led a $100 m Series C financing round for Chinese pharmaceuticals group Innovent Biologics. Singapore-based investment company Temasek, with S$223bn ($178 bn) in AUM also took part in the round said Innovent. PE firms already invested in Innovent include Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures, and Frontline Bioventures. …